Nightingale Health, the Finnish innovator of an internationally recognized blood biomarker testing technology, today announced further steps towards widespread expansion and development of its ...
Board of Directors has resolved to launch a new stock option program for Nightingale Health’s or its group companies’ employees or other key persons. The purpose of Nightingale Health’s stock option ...
Earnings call Nightingale Health delivered 4% revenue growth in H1, with management reiterating its ambitious 50% full-year revenue growth target, heavily weighted to H2 due to project timing.
Nightingale Health, the Finnish innovator of an internationally recognized blood biomarker technology for studying chronic diseases, will analyze the biomarker profiles of 500,000 blood samples from ...
Nightingale Health and Archipelago Health have signed a letter of intent to bring the Nightingale Health Check, a single blood test that detects the risk of several major chronic diseases, to ...
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in ...
19 March, 2021 – Nasdaq (Nasdaq: NDAQ) announces that trading in Nightgale Health Plc shares (short name: HEALTH) commence today on Nasdaq First North Growth Market Finland. The company belongs to ...
Nightingale Health, the Finnish innovator of an internationally recognized blood biomarker technology for studying chronic diseases, will analyse the biomarker profiles of 500,000 blood samples from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results